Tango Therapeutics TNGX
$21.73 −$0.98 (-4.32%)
Market closed · Nov 22, 5:30 am ET · Last extended-hours $22.00 +1.24%
Open$22.11
Prev close$22.71
Day range$21.63 – $23.05
Volume1.74M
Market cap$3.68B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00-100.0% YoY
Operating profit-$78.12M-655.1% YoY
Net profit-$68.39M-530.6% YoY
Diluted EPS-$0.39-400.0% YoY
Free cash flow-$37.20M-19.6% YoY
Operating cash flow-$37.14M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-36.5%
Return on assets-33.5%
Return on invested capital-36.9%
Current ratio39.45
Liabilities / assets5.2%
Cash & investments$977.50M
Total debt$28.12M
Net cash (debt)$949.38M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $0.00 | $0.00 | $62.38M | $0.00 |
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $62.38M | $0.00 |
| Operating Expense | $78.12M | $59.79M | $48.77M | $173.67M | $41.86M |
| Selling and Admin Expenses | $29.19M | $22.59M | $15.24M | $41.51M | $9.76M |
| -General & Admin Expense | $29.19M | $22.59M | $15.24M | $41.51M | $9.76M |
| Research & Development | $48.93M | $37.20M | $33.53M | $132.17M | $32.10M |
| Operating Profit | -$78.12M | -$59.79M | -$48.77M | -$111.29M | -$41.86M |
| Net Non-Operating Interest Income (Expense) | $7.15M | $3.72M | $2.18M | $5.63M | $1.68M |
| Non-Operating Interest Income | $7.15M | $3.72M | $2.18M | $5.63M | $1.68M |
| Other Income (Expense) | $2.57M | $722,000.00 | $1.08M | $4.07M | $1.38M |
| Other Non-Operating Income (Expenses) | $2.57M | $722,000.00 | $1.08M | $4.07M | $1.38M |
| Pretax Profit | -$68.39M | -$55.34M | -$45.51M | -$101.59M | -$38.80M |
| Tax | $0.00 | $1,000.00 | $1,000.00 | $4,000.00 | -$55,000.00 |
| Net Profit | -$68.39M | -$55.34M | -$45.51M | -$101.59M | -$38.75M |
| Profit from Continuing Operations | -$68.39M | -$55.34M | -$45.51M | -$101.59M | -$38.75M |
| Net Income to Parent Company | -$68.39M | -$55.34M | -$45.51M | -$101.59M | -$38.75M |
| Net Income to Common Stockholders | -$68.39M | -$55.34M | -$45.51M | -$101.59M | -$38.75M |
| Basic EPS | -$0.39 | -$0.37 | -$0.32 | -$0.87 | -$0.29 |
| Diluted EPS | -$0.39 | -$0.37 | -$0.32 | -$0.87 | -$0.29 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.03B | $1.07B | $435.79M | $398.69M | $398.69M |
| Total Current Assets | $992.67M | $1.03B | $392.33M | $353.76M | $353.76M |
| Cash and Cash Equivalents & Short-Term Investments | $977.50M | $1.01B | $379.84M | $343.14M | $343.14M |
| -Cash and Cash Equivalents | $86.84M | $345.56M | $157.83M | $112.28M | $112.28M |
| -Short Term Investments | $890.67M | $668.43M | $222.01M | $230.86M | $230.86M |
| Restricted Cash | $0.00 | $0.00 | $0.00 | $428,000.00 | $428,000.00 |
| Other Current Assets | $15.16M | $17.68M | $12.49M | $10.19M | $10.19M |
| Total Non-Current Assets | $40.80M | $42.21M | $43.47M | $44.93M | $44.93M |
| Net PPE | $38.41M | $39.76M | $41.03M | $42.49M | $42.49M |
| -Gross PPE | $50.09M | $51.04M | $51.97M | $53.03M | $53.03M |
| -Accumulated Depreciation | -$11.68M | -$11.29M | -$10.94M | -$10.54M | -$10.54M |
| Other Non-Current Assets | $2.39M | $2.45M | $2.43M | $2.44M | $2.44M |
| Total Liabilities | $53.29M | $49.35M | $44.29M | $52.51M | $52.51M |
| Total Current Liabilities | $25.16M | $20.30M | $14.33M | $21.68M | $21.68M |
| Payables | $1.65M | $1.81M | $2.43M | $1.18M | $1.18M |
| -Accounts Payable | $1.65M | $1.81M | $2.43M | $1.18M | $1.18M |
| Current Accrued Expenses | $18.20M | $12.71M | $7.51M | $16.47M | $16.47M |
| Short-Term Debt and Capital Lease Obligation | $3.06M | $2.94M | $2.83M | $2.74M | $2.74M |
| -Current Capital Lease Obligation | $3.06M | $2.94M | $2.83M | $2.74M | $2.74M |
| Other Current Liabilities | $2.26M | $2.83M | $1.56M | $1.29M | $1.29M |
| Total Non-Current Liabilities | $28.12M | $29.05M | $29.96M | $30.83M | $30.83M |
| Long Term Debt and Capital Lease Obligation | $28.12M | $29.05M | $29.96M | $30.83M | $30.83M |
| -Long Term Capital Lease Obligation | $28.12M | $29.05M | $29.96M | $30.83M | $30.83M |
| Convertible preferred securities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Equity | $980.17M | $1.02B | $391.51M | $346.18M | $346.18M |
| Stockholders' Equity | $980.17M | $1.02B | $391.51M | $346.18M | $346.18M |
| Capital Stock | $169,000.00 | $168,000.00 | $144,000.00 | $136,000.00 | $136,000.00 |
| -Common Stock | $169,000.00 | $168,000.00 | $144,000.00 | $136,000.00 | $136,000.00 |
| Additional Paid-In Capital | $1.76B | $1.73B | $1.04B | $948.97M | $948.97M |
| Retained Earnings | -$772.40M | -$704.01M | -$648.67M | -$603.15M | -$603.15M |
| Gains/Losses Not Affecting Retained Earnings | -$4.51M | -$633,000.00 | -$115,000.00 | $224,000.00 | $224,000.00 |
| Current Deferred Liabilities | – | – | – | $0.00 | $0.00 |
| Non-Current Deferred Liabilities | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$37.14M | -$38.87M | -$44.36M | -$138.89M | -$29.72M |
| Net cash flow from continuing operations | -$37.14M | -$38.87M | -$44.36M | -$138.89M | -$29.72M |
| Net Income from Continuing Operations | -$68.39M | -$55.34M | -$45.51M | -$101.59M | -$38.75M |
| Depreciation & Depletion & Amortization | $420,000.00 | $425,000.00 | $463,000.00 | $2.28M | $479,000.00 |
| Other Non-Cash Items | $1.01M | $970,000.00 | $993,000.00 | $3.88M | $939,000.00 |
| Change in Working Capital | $7.12M | -$866,000.00 | -$9.98M | -$67.20M | $2.40M |
| -Change in Prepaid Assets | $2.52M | -$5.19M | -$2.30M | -$1.76M | $350,000.00 |
| -Change in Payables and Accrued Expense | $5.35M | $5.14M | -$6.91M | $279,000.00 | $3.26M |
| -Change in Other Current Assets | $66,000.00 | -$19,000.00 | $10,000.00 | -$299,000.00 | -$13,000.00 |
| -Change in Other Current Liabilities | -$813,000.00 | -$797,000.00 | -$781,000.00 | -$3.03M | -$1.19M |
| Net cash flow from investing | -$223.98M | -$445.97M | $9.64M | -$40.87M | -$135.72M |
| Net Cash Flow from Continuing Investing Activities | -$223.98M | -$445.97M | $9.64M | -$40.87M | -$135.72M |
| Net PPE Purchase and Sale | -$77,000.00 | $20,000.00 | $2,000.00 | -$1.05M | -$222,000.00 |
| Net Investment Purchase and Sale | -$223.91M | -$445.99M | $9.63M | -$39.82M | -$135.50M |
| Financing Cash Flow | $2.40M | $672.57M | $79.85M | $222.50M | $219.38M |
| Net Cash Flow from Continuing Financing Activities | $2.40M | $672.57M | $79.85M | $222.50M | $219.38M |
| Net Common Stock Issuance | $0.00 | $652.04M | $62.78M | $212.40M | $212.40M |
| Proceeds from Stock Option Exercised | $3.05M | $20.62M | $17.61M | $10.14M | $7.01M |
| Net Other Financing Charges | -$643,000.00 | -$95,000.00 | -$537,000.00 | -$36,000.00 | – |
| Ending Cash Balance | $88.97M | $347.70M | $159.97M | $114.85M | $114.85M |
| Net Change in Cash | -$258.72M | $187.73M | $45.12M | $42.75M | $53.94M |
| Beginning Cash Balance | $347.70M | $159.97M | $114.85M | $72.10M | $60.91M |
| Free Cash Flow | -$37.20M | -$38.87M | -$44.36M | -$139.93M | -$29.94M |
| -Change in Receivables | – | – | – | $0.00 | – |
| -Change In Other Working Capital | – | – | – | -$62.38M | $0.00 |
No comments yet — be the first to weigh in on TNGX.
Sign in to join the discussion.